Jurisdiction	Recommendation	Details	Date	Level of evidence	Strength of recommendation
Latin America 18	Latin American consensus on management of residual cardiometabolic risk	After myocardial infarction and patients with evidence of stable coronary disease, after treatment with statins, aspirin and ACEI/ARB	June 2021	IIb	B
Europe 19	Guidelines on cardiovascular disease prevention in clinical practice	May be considered in secondary prevention of cardiovascular disease, particularly if other risk factors are insufficiently controlled or if recurrent cardiovascular disease events occur under optimal therapy	September 2021	IIb	A
Canada 20	Health Canada	May be considered for the reduction of atherothrombotic events in adults with existing coronary heart disease in addition to standard therapies, including LDL cholesterol‐lowering and antithrombotic therapies	August 2021

ACEI = angiotensin‐converting enzyme inhibitor; ARB = angiotensin II receptor antagonist; LDL = low‐density lipoprotein.